TAMPA, Fla. , Sept. 9, 2024 /PRNewswire/ -- WellSync , a leader in telehealth innovation, is excited to announce a collaboration with Marius Pharmaceuticals to offer KYZATREX ® (testosterone undecanoate) CIII capsules, an oral form of testosterone replacement therapy (TRT) on WellSync's comprehensive virtual care platform .
This initiative demonstrates WellSync's ability to integrate seamlessly with pharmaceutical products, delivering an innovative direct-to-patient healthcare solution. WellSync's dynamic virtual-first platform handles every aspect of the patient journey — from initial lab services that pre-qualify patients for treatment to comprehensive virtual consultations, personalized treatment plans, and medication fulfillment. Orders will be reviewed and, pending approval, fulfilled and discreetly shipped via a URAC-accredited partner pharmacy directly to the patient's doorstep.
This end-to-end solution enables drug manufacturing companies like Marius Pharmaceuticals to reach patients more efficiently and at a reasonable price, ensuring that treatments like KYZATREX are delivered with the highest level of care and convenience. "Our work with Marius Pharmaceuticals represents a significant step forward in our mission to transform the way healthcare is delivered," said Clint House , CEO of WellSync. "By offering KYZATREX through our virtual care platform, we're delivering a streamlined, accessible, and effective solution for men's health that seamlessly integrates int.